Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth 1 ABBOTT PARK , Ill. , April 17, 2024 /PRNewswire/ -- Abbott (NYSE:... Read More

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. are affected by tricuspid regurgitation, 1 which can severely impact quality of life Data from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of... Read More

The test, run on Abbott's portable i-STAT ® Alinity ® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion The test produces lab-quality results in 15 minutes Clinicians are now able to get a result at the patient's bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room The test can be... Read More

ABBOTT PARK , Ill. , March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call... Read More

Abbott's Eterna™ SCS system to treat chronic pain was used for the first time in Canada at Hôpital de l'Enfant-Jésus hospital in Quebec City . The device is the smallest implantable rechargeable spinal cord stimulator (SCS) *3 and provides the ability to deliver therapy while only requiring wireless recharging five times per year, 1,2 meaning less frequent charging for the chronic pain patients being treated. §4 MONTRÉAL ,... Read More

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results were achieved irrespective of GLP-1 duration, GLP-1 type, or insulin therapy type FreeStyle Libre systems help people adhere to... Read More

ABBOTT PARK , Ill. , Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 401 st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024 . Abbott has increased its dividend payout for 52 consecutive years... Read More

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK , Ill. , Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the... Read More

Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre-donation anxiety said the mixed reality experience helped ease feelings of anxiety 89.2% of donors who tried mixed reality said they were likely to donate blood again Innovation is designed to attract new donors and motivate a... Read More

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in... Read More

Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest time between charges of any DBS technology on the market, allowing people with movement disorders to recharge the device only 10 times a year 2 * ABBOTT PARK , Ill. , Jan. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced... Read More

Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underlying base business increased 11.6 percent Full-year 2023 GAAP diluted EPS of $3.26 ; adjusted diluted EPS of $4.44 R&D pipeline continues to deliver... Read More

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing... Read More

ABBOTT PARK , Ill. , Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call... Read More

ABBOTT PARK , Ill. , Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42 nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024 . Robert B. Ford , chairman and chief executive officer, will present at 11 a.m. Central time . A live webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . About Abbott Abbott is a global healthcare... Read More

Dividend increased by 7.8% 400 th consecutive quarterly dividend to be paid by Abbott since 1924 Company continues to deliver strong shareholder returns and top-tier growth ABBOTT PARK , Ill. , Dec. 15, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 55 cents per share, an increase of 7.8%. This marks the company's 52 nd consecutive... Read More

New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots More than 30,000 people worldwide have received Abbott's life-saving heart pump to overcome advanced heart failure ABBOTT PARK , Ill. , Nov. 13, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced new late-breaking... Read More

Study by Public Health Institute shows people with diabetes were able to lower A1C levels, better self-manage diabetes, and improve overall diet and food security at 12 months Abbott's Healthy Food Rx program provides home-delivered healthy food boxes to help address diabetes; part of broader collaboration to address social barriers and expand access to health in Stockton, Calif. ABBOTT PARK, Ill. and OAKLAND, Calif. , Nov.... Read More

According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancer Abbott's new HPV test uses molecular technology to provide genotype determination on the 14 high-risk, cancer-causing types of HPV The test is one of the few i HPV tests approved for use as a primary screen for cervical cancer as recommended by... Read More

Abbott and Shepherd aim to raise awareness of the rising rates of diabetes diagnoses and how access to continuous glucose monitoring (CGM) systems can reduce diabetes-related complications 1 , provide better health outcomes, and improve quality of living 2 Television host and diabetes advocate Sherri Shepherd unveils... Read More

HeartMates will create a supportive and empowering community for people impacted by heart conditions, leveraging Abbott's leadership in cardiovascular care Professional football player and heart health advocate Damar Hamlin joins Abbott to kick off the HeartMates program Heart disease impacts over 100 million Americans, nearly... Read More

New survey by Morning Consult on behalf of Abbott shows student loans are having a profound and far-reaching impact on young adults and their planning for the future 91% say financial stress is impacting their mental, physical wellness and student loan debt is a key driver of this financial stress 94% are interested in a workplace benefit in which they get an employer-provided 401(k) contribution as they pay off their school... Read More

Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged artery There is a significant need for more treatments: there are currently no drug-eluting stents, drug-coated balloons or bare-metal stents approved for below the knee (BTK) use in the U.S. Abbott's landmark LIFE-BTK randomized clinical... Read More

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S. One-year outcomes from the EXPAND G4 study, simultaneously published in JACC: Cardiovascular Interventions , reinforce durable safety and... Read More

Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 13.8 percent, reflects double-digit growth in each of the four major businesses ABBOTT PARK , Ill. , Oct. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial... Read More

ABBOTT PARK , Ill. , Sept. 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call... Read More

ABBOTT PARK , Ill. , Sept. 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott's presence in diabetes care, building on its world-leading FreeStyle Libre ® portfolio of continuous glucose monitoring technology and furthering the company's efforts to... Read More

ABBOTT PARK , Ill. , Sept. 21, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 399 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2023, to shareholders of record at the close of business on Oct. 13, 2023 . Abbott has increased its dividend payout for 51 consecutive years... Read More

Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America , Southeast Asia , the Middle East and Africa Spain -based global biotech leader mAbxience Holdings S.L. to develop, manufacture and supply the biosimilar molecules First molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging markets... Read More

Abbott introduced the world's first ablation catheter with a flexible tip and contact force technology, used to perform an ablation procedure to treat atrial fibrillation (AFib) First successful treatment in Canada - Abbott's innovative technology enables physicians to have better visualization allowing for more accuracy and precision, leading to reduced procedure times and better safety MISSISSAUGA, ON , Sept. 19, 2023... Read More

The #1 prescribed continuous glucose monitoring (CGM) system 1 now connects to the #1 doctor-recommended weight management plan 2 to help people living with diabetes understand how food and activity impact their glucose levels WeightWatchers Diabetes-Tailored Plan members can now see key glucose data 3,4,5 from Abbott's FreeStyle Libre ® 2 system within the WW app 6 ABBOTT PARK, Ill. and NEW YORK , Sept. 19, 2023... Read More

Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support Together, Abbott and... Read More

Sales of $10.0 billion driven by strong underlying base business performance Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 11.5 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition Continues to strengthen portfolio with new product approvals and expanded reimbursement coverage... Read More

Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA battery Leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow or abnormal heart rhythms Approval comes on the heels of recent late-breaking... Read More

ABBOTT PARK , Ill. , June 29, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2023 financial results on Thursday, July 20 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time ( 9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the... Read More

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous glucose monitoring (CGM) systems, serving a greater population of people living with diabetes France is the first country in Europe to grant national reimbursement for people who use basal insulin, following similar... Read More

ABBOTT PARK , Ill. , June 9, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 398 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2023, to shareholders of record at the close of business on July 14, 2023 . Abbott has increased its dividend payout for 51 consecutive years... Read More

Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to work together to reduce malnutrition Campaign will supply malnutrition screening tools to local communities and provide funding for malnutrition programs at Real Madrid Foundation... Read More

MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients CardioMEMS is a paperclip-sized sensor that can remotely flag to a patient's clinical team the early warning signs of worsening heart failure ABBOTT PARK , Ill. , May 24, 2023 /PRNewswire/ -- New data presented from an investigator-sponsored European trial found managing indicated 1 heart... Read More

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott's investigational AVEIR DR leadless pacemakers have been submitted for... Read More

TactiFlex™ Ablation Catheter, Sensor Enabled™, is the world's first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation When used with Abbott's EnSite™ X EP System, physicians have better visualization allowing for more accuracy and precision with the TactiFlex catheter, leading to reduced procedure times and better safety ABBOTT PARK , Ill. ,... Read More

Abbott's Assert-IQ offers the world's longest battery life† for an insertable cardiac monitor (ICM) The latest addition to Abbott's portfolio of connected health devices, the Assert-IQ ICM offers long-term monitoring and remote programming to improve connectivity to patients The device provides continuous monitoring for... Read More

FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic back pain when surgery is not an option Results for the first 200 patients demonstrated that people who used the company's SCS products experienced significant relief and improvements in pain, function, quality of life and psychological status 1 , 2 Prior to enrollment in the... Read More

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of... Read More

ABBOTT PARK , Ill. , April 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for... Read More

Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians... Read More

Abbott is joining the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which will use data science to predict, track and control diseases that may be amplified by climate change A changing climate may increase the spread of both known and unknown viruses, particularly those transmitted by water or animals carrying diseases CLIMADE's initial work will start with disease surveillance in Africa and expand to... Read More

Sales of $9.7 billion driven by strong underlying base business performance Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition ABBOTT PARK , Ill. , April 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial... Read More

The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using 1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections Medicare beneficiaries with diabetes and a history of problematic hypoglycemia 2 may also be eligible to have their FreeStyle Libre 2 system or... Read More

The FreeStyle Libre 3 system is the latest generation in Abbott's FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the United States 1, 2 With a standalone reader, Abbott is working 3 to have the FreeStyle Libre 3 system available to Medicare beneficiaries... Read More

ABBOTT PARK , Ill. , March 29, 2023 /PRNewswire/ -- Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call will... Read More

The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of getting concussions evaluated Concussion Awareness Now is a coalition of nearly 20 advocacy groups, founded by Abbott and the Brain Injury Association of America, with Rebel Wilson as the group's inaugural spokesperson The campaign addresses the fact that more than half of people who... Read More

New test will run on Abbott's Alinity® i laboratory instrument, complementing Abbott's rapid i-STAT TBI Plasma test, cleared by the FDA in 2021 Given the significant number of Alinity i instruments in use in labs across the U.S., Abbott's lab test will make concussion testing available to more people across the country Test helps doctors evaluate patients with mild traumatic brain injury (mTBI), commonly known as concussion,... Read More

Abbott's world's leading 1 and affordable 2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also cleared for use by children as young as two years old, for use by women with diabetes who are pregnant, and for wear time up to... Read More

New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine reinforce the long-term safety and effectiveness of MitraClip for treating secondary mitral regurgitation (MR) Results show minimally invasive mitral valve repair in advanced heart failure patients reduces hospitalizations and deaths and provides durable reduction in... Read More

Late-breaking data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine demonstrate TriClip was superior to medical therapy with significant improvements in quality of life and tricuspid regurgitation (TR) Findings show TriClip, an investigational device in the U.S. to treat a leaky tricuspid valve, demonstrated safety and met the primary... Read More

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder's immediate and complete closure of the LAA compared to Watchman‡ Findings underscore the importance of innovative, minimally invasive treatment options for... Read More

Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease ABBOTT PARK , Ill. , Jan. 17, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the... Read More

Mixed reality offers donors an innovative, immersive digital experience while giving blood The Abbott technology is one of the first-ever, consumer-focused mixed reality applications completely controlled through eye tracking Innovation aims to improve the experience and attract new, younger blood donors by adding an element... Read More

ABBOTT PARK , Ill. , Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023 , before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the... Read More

First automated insulin delivery (AID) system in the world to work with Abbott's FreeStyle Libre ® 3 sensor Automated process streamlines and improves daily diabetes management for people who are on insulin therapy 1 Hybrid closed-loop system mylife ™ Loop incorporates technology from two partners: CamDiab's algorithm... Read More

ABBOTT PARK , Ill. , Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023 . Robert B. Ford , chairman and chief executive officer, will present at 11 a.m. Central time . A live webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the presentation... Read More

The U.S. Food and Drug Administration (FDA) approved Abbott's Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic pain This neuromodulation device provides an optimized experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable SCS systems §1,2,3 ABBOTT PARK , Ill. , Dec. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today... Read More

Concussion Awareness Now is comprised of nearly 20 advocacy groups focused on brain injury and will work to raise awareness about the importance of diagnosis and treatment for concussions The vast majority of concussions happen in everyday accidents, and over half of people who suspect they have a concussion never get it checked Rebel Wilson sustained a concussion while on set producing and acting in a movie and is sharing... Read More

Dividend increased by 8.5% Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns ABBOTT PARK , Ill. , Dec. 9, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an increase of 8.5%. This marks the company's 51 st consecutive year of dividend growth. It will be the 396 th consecutive... Read More